drugset / Trial / NCT00154011

Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.

NCT00154011

Completed 24 enrolled Technical University Dresden
RandomizedParallel-groupDouble-blindTreatment

Summary

The study is designed to test the hypothesis in healthy subjects that the oral antidiabetic drug rosiglitazone provides additional vascular relaxing or modulating effects in addition to its blood glucose level reducing ability.

Timeline

Start
2005-09
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule 8 mg Oral

Indications

No indication recorded.